Acousia has raised $11.8m from backers including Boehringer Ingelheim Venture Fund to advance therapies for inner-ear impairments into the clinic.

Celgene was among the investors helping the cancer cell-therapy developer increase its total funding to approximately $110m.

Celsius Therapeutics, which has launched with series A capital, has become the latest Third Rock-launched company to be backed by GV.

Polyphor, which has collaboration agreements in place with multiple pharmaceutical companies, raised $155m when it floated on the SIX Swiss Exchange.

University of Birmingham has spun out Viatem to develop a treatment for rheumatoid arthritis.

The Cambridge spinout has raised $15m in series A funding from investors including Cambridge Enterprise and Parkwalk Advisors.

Baylor College of Medicine immuno-oncology spinout Marker Therapeutics is to merge with publicly-listed TapImmune, which has set up a $70m private placement to support the new entity.

NewYork-Presbyterian Hospital was among the backers in a round that took the healthcare planning platform's total funding to more than $43m.